Otite media cronica non colesteatomatosa: fisiopatologia e forme cliniche

Autor: Billon-Galland, L., Hermann, R., Coudert, A., Truy, E.

Publikováno v: In EMC – Otorinolaringoiatria March 2022 21(1):1-16

Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.

Autor: Ladoire S; Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France; INSERM U1231, Université de Bourgogne, 21000, Dijon, France; Université de Bourgogne, 21000, Dijon, France. Electronic address: sladoire@cgfl.fr., Mamguem Kamga A; INSERM U1231, Université de Bourgogne, 21000, Dijon, France; Breast and Gynaecologic Cancer Registry of Côte d'Or, Epidemiology and Quality of Life Research Unit, Georges-François Leclerc Comprehensive Cancer Centre-UNICANCER, 1 rue du Professeur Marion, 21000, Dijon, France., Galland L; Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France., Desmoulins I; Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France., Mayeur D; Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France., Kaderbhai C; Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France., Ilie SM; Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France., Hennequin A; Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France., Jankowski C; Department of Surgical Oncology Centre Georges-François Leclerc 1 rue du Professeur Marion, 21000, Dijon, France., Albuisson J; INSERM UMR 1231 GIMI, Genomic and Immunotherapy Medical Institute, Université Bourgogne Franche-Comté, Dijon, France; Unité de Biologie Moléculaire, Centre de Lutte Contre le Cancer Georges François Leclerc-UNICANCER, Dijon, France., Nambot S; INSERM UMR 1231 GIMI, Genomic and Immunotherapy Medical Institute, Université Bourgogne Franche-Comté, Dijon, France; Centre de Génétique, FHU-TRANSLAD, Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France; INSERM UMR 1231 GAD, Génétique des Anomalies du Développement, Université Bourgogne Franche-Comté, Dijon, France; Unité d'Oncogénétique, Centre de Lutte Contre le Cancer Georges François Leclerc-UNICANCER, Dijon, France., Coutant C; Université de Bourgogne, 21000, Dijon, France; Department of Surgical Oncology Centre Georges-François Leclerc 1 rue du Professeur Marion, 21000, Dijon, France., Arnould L; Department of Biology and Pathology of Tumors. Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France., Reda M; Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France; Unité d'Oncogénétique, Centre de Lutte Contre le Cancer Georges François Leclerc-UNICANCER, Dijon, France., Truntzer C; Platform of Transfer in Biological Oncology - Georges François Leclerc Cancer Center, Dijon, France., Dabakuyo S; INSERM U1231, Université de Bourgogne, 21000, Dijon, France; Breast and Gynaecologic Cancer Registry of Côte d'Or, Epidemiology and Quality of Life Research Unit, Georges-François Leclerc Comprehensive Cancer Centre-UNICANCER, 1 rue du Professeur Marion, 21000, Dijon, France.

Publikováno v: Breast (Edinburgh, Scotland) [Breast] 2024 Dec; Vol. 78, pp. 103789. Date of Electronic Publication: 2024 Aug 28.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.

Autor: Frenel JS; Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France., Zeghondy J; Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France., Guérin-Charbonnel C; Department of Biostatistics and Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France., Mailliez A; Department of Medical Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France., Volant E; Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France., Poumeaud F; Department of Medical Oncology, Oncopôle, Toulouse, France., Patsouris A; Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Angers, France., Arnedos M; Department of Medical Oncology Bordeaux, Institut Bergonie, Bordeaux, France., Bailleux C; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France., Cabal J; Department of Medical Oncology, Centre Eugene Marquis, Rennes, France., Galland L; Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France., de Nonneville A; Department of Medical Oncology, Institut Paoli Calmette, Marseille, France., Guiu S; Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France., Dalenc F; Department of Medical Oncology, Oncopôle, Toulouse, France., Pistilli B; Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France., Bachelot T; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Pierga JY; Department of Medical Oncology, Institut Curie, Paris, France., Le Du F; Department of Medical Oncology, Centre Eugene Marquis, Rennes, France., Bocquet F; Data Factory, Institut de Cancerologie de l'Ouest, Saint-Herblain, France., Larrouquere L; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Loirat D; Department of Medical Oncology, Institut Curie, Paris, France.

Publikováno v: JAMA network open [JAMA Netw Open] 2024 Apr 01; Vol. 7 (4), pp. e244435. Date of Electronic Publication: 2024 Apr 01.

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.

Autor: Roussot N; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.; Cancer Biology Transfer Platform, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France., Fumet JD; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France. jdfumet@cgfl.fr.; Cancer Biology Transfer Platform, Dijon, France. jdfumet@cgfl.fr., Limagne E; Cancer Biology Transfer Platform, Dijon, France.; GIMI Genetic and Immunology Medical Institute, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France., Thibaudin M; Cancer Biology Transfer Platform, Dijon, France.; GIMI Genetic and Immunology Medical Institute, Dijon, France.; UMR INSERM 1231, Dijon, France., Hervieu A; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France., Hennequin A; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France., Zanetta S; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France., Dalens L; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France., Fourrier T; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France., Galland L; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France., Jacob P; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France., Bertaut A; Department of Epidemiology and Biostatistics, Center GF Leclerc, Dijon, France., Rederstorff E; Department of Epidemiology and Biostatistics, Center GF Leclerc, Dijon, France., Chevalier C; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Ghirardi S; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Gilbert E; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Khoukaz A; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Martin E; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Nicolet C; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Quivrin M; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Thibouw D; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Vulquin N; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Truc G; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Rouffiac M; Department of Radiotherapy, Center GF Leclerc, Dijon, France., Ghiringhelli F; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.; Cancer Biology Transfer Platform, Dijon, France.; GIMI Genetic and Immunology Medical Institute, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France., Mirjolet C; UMR INSERM 1231, Dijon, France.; Radiation Oncology Department, Preclinical Radiation Therapy and Radiobiology Unit, Center GF Leclerc, Unicancer, Dijon, France.

Publikováno v: BMC cancer [BMC Cancer] 2023 Nov 09; Vol. 23 (1), pp. 1080. Date of Electronic Publication: 2023 Nov 09.